RAD51D, a gene in the Fanconi Anemia–BRCA homologous recombination pathway, has recently been shown to harbor germline mutations responsible for ovarian carcinoma in multiply affected families. We aimed to extend these results to ovarian carcinoma in the general population.
We sequenced RAD51D in germline DNA from 360 individuals with primary ovarian, peritoneal or fallopian tube carcinoma who were not selected for age of cancer onset or family history. We also sequenced RAD51D in 459 probands from 226 high risk breast cancer families who were wild type for 21 breast and ovarian cancer genes.
Of 360 cases, three (0.8%) carried loss-of-function mutations in RAD51D. All three subjects had ovarian carcinoma; one was also diagnosed with a synchronous endometrial carcinoma. Only one of the three subjects had a family history of breast or ovarian cancer. Combined with previous data for this series, 23.9% of women with unselected ovarian, fallopian tube, or peritoneal carcinoma carried a germline loss-of-function mutation in any of 13 tumor suppressor genes. Among the 449 women and 10 men with familial breast cancer, none carried a loss of function mutation in RAD51D.
These data support the previous observation that loss-of-function mutations in RAD51D predispose to ovarian carcinoma but not to breast carcinoma. We conclude that inherited ovarian cancer is highly heterogeneous genetically, and that approximately one in four ovarian carcinoma patients carry a germline mutation in a known tumor suppressor gene that confers high risk.
- RAD51D loss-of-function mutations are present in 1% of unselected women with ovarian cancer.
- Ovarian cancer risk assessment should include evaluation of RAD51D in a multigene panel.
- Women with ovarian cancer should be evaluated for hereditary risk without selection for family history.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.Proc Natl Acad Sci U S A. 2011; 108: 18032-18037
- Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.J Clin Oncol. 2008; 26: 1331-1337
- Germline mutations in RAD51D confer susceptibility to ovarian cancer.Nat Genet. 2011; 43: 879-882
- Identification and purification of two distinct complexes containing the five RAD51 paralogs.Genes Dev. 2001; 15: 3296-3307
- Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.Br J Cancer. 2012; 106: 1460-1463
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.Proc Natl Acad Sci U S A. 2010; 107: 12629-12633
- Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.Cancer Res. 2011; 71: 2222-2229
Accepted: September 9, 2012
Received: June 21, 2012
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Corrigendum to: Loss of function germline mutations in RAD51D in women with ovarian carcinoma [Gynecol Oncol 127: 552–555, 2012]Gynecologic OncologyVol. 132Issue 1